Morgan Stanley’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.7M | Sell |
507,127
-416,545
| -45% | -$4.68M | ﹤0.01% | 3953 |
|
|
2025
Q1 | $4.22M | Buy |
923,672
+124,731
| +16% | +$570K | ﹤0.01% | 4069 |
|
|
2024
Q4 | $4.51M | Sell |
798,941
-114,250
| -13% | -$644K | ﹤0.01% | 4087 |
|
|
2024
Q3 | $4.42M | Buy |
913,191
+289,461
| +46% | +$1.4M | ﹤0.01% | 4053 |
|
|
2024
Q2 | $3.04M | Sell |
623,730
-261,836
| -30% | -$1.28M | ﹤0.01% | 4272 |
|
|
2024
Q1 | $11.8M | Buy |
885,566
+191,764
| +28% | +$2.55M | ﹤0.01% | 3210 |
|
|
2023
Q4 | $9.67M | Buy |
693,802
+397,574
| +134% | +$5.54M | ﹤0.01% | 3945 |
|
|
2023
Q3 | $3.93M | Sell |
296,228
-45,826
| -13% | -$608K | ﹤0.01% | 3923 |
|
|
2023
Q2 | $6.41M | Buy |
342,054
+101,233
| +42% | +$1.9M | ﹤0.01% | 3571 |
|
|
2023
Q1 | $3.47M | Buy |
240,821
+143,878
| +148% | +$2.07M | ﹤0.01% | 4080 |
|
|
2022
Q4 | $1.88M | Sell |
96,943
-35,383
| -27% | -$685K | ﹤0.01% | 4510 |
|
|
2022
Q3 | $4.55M | Sell |
132,326
-65,220
| -33% | -$2.24M | ﹤0.01% | 3778 |
|
|
2022
Q2 | $3.02M | Sell |
197,546
-19,226
| -9% | -$294K | ﹤0.01% | 4203 |
|
|
2022
Q1 | $4.95M | Buy |
216,772
+199,616
| +1,164% | +$4.55M | ﹤0.01% | 3697 |
|
|
2021
Q4 | $632K | Buy |
17,156
+11,267
| +191% | +$415K | ﹤0.01% | 5403 |
|
|
2021
Q3 | $276K | Buy |
5,889
+3,421
| +139% | +$160K | ﹤0.01% | 5826 |
|
|
2021
Q2 | $149K | Buy |
+2,468
| New | +$149K | ﹤0.01% | 6164 |
|